超碰97人人爱人人做-超碰97人人操-超碰97人人操人人干-超碰97人人操人人摸-超碰97人人艹-超碰97人人干人人爱

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Quikin CAR-T Platform


The Quikin CAR-T Platform (Quikin CART) generates T cell products with gene knockout and stable integration of CAR cassette in one step through CRISPR gene editing technology. As a new generation of CAR-T platform, it has several advantages, including simplified manufacturing process, shortened preparation time, higher product uniformity and avoiding the risk of tumorigenesis caused by random integration. The product with integration of anti-CD19 CAR cassette into PD1?locus combines PD1 immune checkpoint inhibition with CART anti-tumor activity. This platform has the potential to prepare enhanced CAR-T cells with gene knockout of multiple immune checkpoints, rapidly produce universal CAR-T cells and prepare dynamically regulated CAR-T cells with high safety, thus providing strong technical support for future improvement of CAR-T cells.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 国产极品美乳尤物在线 | 成人免费看片又大又黄 | 亚洲中文字幕久 | 国产日韩成人精品视频 | 免费成年人看的视频品爱网 | 亚洲国产欧美精品一区二区三区 | 国产精品一区二区制服 | 扒开老师大| 亚洲美女视频网 | 99国产第一页在线 | 欧美日韩国产精品视频一区二 | 欧美一级日韩国产 | 精品视频免费看天天春夜夜春 | 91黑料吃瓜在线观看 | 免费观看视频成人国产 | 海量正版高清视频在线观看 | 国产亚洲视频网站 | 成人国产欧美精品一区二区 | 国产精品成人一二三区 | 一区二区三区精品视频免费播放 | 美国十次啦| 放荡的美妇在线播放 | 亚洲免费在线观看一区二区 | 男女午夜视频在线观 | 国产一区在线免费 | 精品亚洲欧美日韩 | 亚洲的一区二区精品 | 成人福利在线视频免费观看 | 久精品在线观看 | 国语自产拍在线观看对白 | 日本一区二区三区视频在线 | 国内性色精 | 日本黄大片在线观看播放 | 午夜爽片超清 | 日韩欧美二区三区精品 | 国产精品jlzz视频 | 欧美在线a级一区二区三区 精品蜜桃 | 欧美人成| 国产一区二区xxx | h的动漫在线观看亚洲一区 片免费看 | 姐妹5中国版 |